Medline (MDLN) Stock Forecast & Price Target

Compare

236 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

MDLN Analyst Ratings

Strong Buy

23 Buy

4 Hold

0 Sell

Based on 27 analysts giving stock ratings to

Medline

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

MDLN Stock 12 Month Forecast

Average Price Target

$52.35

▲(17.50% Upside)

Based on 27 Wall Street analysts offering 12 month price targets for Medline in the last 3 months. The average price target is $52.35 with a high forecast of $60.00 and a low forecast of $38.00. The average price target represents a 17.50% change from the last price of $44.55.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"37":"$37","43":"$43","49":"$49","55":"$55","61":"$61"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$60.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":52.34615384615385,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$52.35</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$38.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[37,43,49,55,61],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,45.85,46.93846153846154,48.026923076923076,49.11538461538461,50.20384615384616,51.292307692307695,52.38076923076923,53.46923076923077,54.55769230769231,55.64615384615385,56.73461538461538,57.823076923076925,58.91153846153846,{"y":60,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,45.85,46.34970414201184,46.84940828402367,47.349112426035504,47.84881656804734,48.34852071005918,48.848224852071006,49.34792899408284,49.84763313609468,50.34733727810651,50.847041420118344,51.34674556213018,51.84644970414201,{"y":52.34615384615385,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,45.85,45.246153846153845,44.642307692307696,44.03846153846154,43.434615384615384,42.830769230769235,42.22692307692308,41.62307692307692,41.019230769230774,40.41538461538462,39.81153846153846,39.20769230769231,38.603846153846156,{"y":38,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":41,"date":1740787200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":41,"date":1743465600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":41,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":41,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":41,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":41,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":41,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":41,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":41,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":41,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":42,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.02,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.85,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$60.00

Average Price Target$52.35

Lowest Price Target$38.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Patrick B Donnelly

Citi

$60

Buy

34.68%

Upside

Reiterated

03/11/26

Medline resumed with a Buy at CitiMedline resumed with a Buy at Citi

Lisa Gill

J.P. Morgan

$50→$53

Buy

18.97%

Upside

Assigned

03/10/26

Medline price target raised to $53 from $50 at JPMorganMedline price target raised to $53 from $50 at JPMorgan

Ivan Feinseth

Tigress Financial

$55→$60

Buy

34.68%

Upside

Reiterated

03/09/26

Medline price target raised to $60 from $55 at Tigress FinancialMedline price target raised to $60 from $55 at Tigress Financial

David Larsen

BTIG

$55

Buy

23.46%

Upside

Reiterated

03/09/26

Analysts Are Bullish on These Healthcare Stocks: Dexcom (DXCM), Medline (MDLN)

Jailendra Singh

Truist Financial

$52→$56

Buy

25.70%

Upside

Reiterated

03/03/26

Medline price target raised to $56 from $52 at TruistMedline price target raised to $56 from $52 at Truist

Brandon Vazquez

William Blair

―

Buy

―

Reiterated

03/02/26

Analysts' Top Healthcare Picks: Trulieve Cannabis (TCNNF), Medline (MDLN)

Charles Rhyee

TD Cowen

$46→$53

Buy

18.97%

Upside

Reiterated

03/01/26

Conservative 2026 Guidance and Strong Segment Fundamentals Underpin Buy Rating and $53 Target for Medline

Stephen Baxter

Wells Fargo

$42→$47

Hold

5.50%

Upside

Reiterated

02/27/26

Medline price target raised to $47 from $42 at Wells FargoMedline price target raised to $47 from $42 at Wells Fargo

David Roman

Goldman Sachs

$49→$54

Buy

21.21%

Upside

Reiterated

02/27/26

Analysts Offer Insights on Healthcare Companies: Medline, Inc. Class A (NASDAQ: MDLN), Mirum Pharmaceuticals (NASDAQ: MIRM) and Alcon (NYSE: ALC)

Andrew Obin

Bank of America Securities

$50→$55

Buy

23.46%

Upside

Reiterated

02/26/26

Analysts Offer Insights on Healthcare Companies: Schrodinger (NASDAQ: SDGR), Medline, Inc. Class A (NASDAQ: MDLN) and Silence Therapeutics (NASDAQ: SLN)

Eric Coldwell

Robert W. Baird

$48→$56

Buy

25.70%

Upside

Reiterated

02/26/26

Medline price target raised to $56 from $48 at BairdMedline price target raised to $56 from $48 at Baird

Pito Chickering

Deutsche Bank

$40→$48

Hold

7.74%

Upside

Reiterated

02/26/26

Medline price target raised to $48 from $40 at Deutsche BankMedline price target raised to $48 from $40 at Deutsche Bank

Glen Santangelo

Barclays

$50

Buy

12.23%

Upside

Reiterated

02/26/26

Barclays Sticks to Its Buy Rating for Medline, Inc. Class A (MDLN)

Kevin Caliendo

UBS

$48→$57

Buy

27.95%

Upside

Reiterated

02/26/26

Medline price target raised to $57 from $48 at UBSMedline price target raised to $57 from $48 at UBS

Lee Hambright

Bernstein

$49→$56

Buy

25.70%

Upside

Assigned

02/26/26

Medline price target raised to $56 from $49 at BernsteinMedline price target raised to $56 from $49 at Bernstein

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Patrick B Donnelly

Citi

$60

Buy

34.68%

Upside

Reiterated

03/11/26

Medline resumed with a Buy at CitiMedline resumed with a Buy at Citi

Lisa Gill

J.P. Morgan

$50→$53

Buy

18.97%

Upside

Assigned

03/10/26

Medline price target raised to $53 from $50 at JPMorganMedline price target raised to $53 from $50 at JPMorgan

Ivan Feinseth

Tigress Financial

$55→$60

Buy

34.68%

Upside

Reiterated

03/09/26

Medline price target raised to $60 from $55 at Tigress FinancialMedline price target raised to $60 from $55 at Tigress Financial

David Larsen

BTIG

$55

Buy

23.46%

Upside

Reiterated

03/09/26

Analysts Are Bullish on These Healthcare Stocks: Dexcom (DXCM), Medline (MDLN)

Jailendra Singh

Truist Financial

$52→$56

Buy

25.70%

Upside

Reiterated

03/03/26

Medline price target raised to $56 from $52 at TruistMedline price target raised to $56 from $52 at Truist

Brandon Vazquez

William Blair

―

Buy

―

Reiterated

03/02/26

Analysts' Top Healthcare Picks: Trulieve Cannabis (TCNNF), Medline (MDLN)

Charles Rhyee

TD Cowen

$46→$53

Buy

18.97%

Upside

Reiterated

03/01/26

Conservative 2026 Guidance and Strong Segment Fundamentals Underpin Buy Rating and $53 Target for Medline

Stephen Baxter

Wells Fargo

$42→$47

Hold

5.50%

Upside

Reiterated

02/27/26

Medline price target raised to $47 from $42 at Wells FargoMedline price target raised to $47 from $42 at Wells Fargo

David Roman

Goldman Sachs

$49→$54

Buy

21.21%

Upside

Reiterated

02/27/26

Analysts Offer Insights on Healthcare Companies: Medline, Inc. Class A (NASDAQ: MDLN), Mirum Pharmaceuticals (NASDAQ: MIRM) and Alcon (NYSE: ALC)

Andrew Obin

Bank of America Securities

$50→$55

Buy

23.46%

Upside

Reiterated

02/26/26

Analysts Offer Insights on Healthcare Companies: Schrodinger (NASDAQ: SDGR), Medline, Inc. Class A (NASDAQ: MDLN) and Silence Therapeutics (NASDAQ: SLN)

Eric Coldwell

Robert W. Baird

$48→$56

Buy

25.70%

Upside

Reiterated

02/26/26

Medline price target raised to $56 from $48 at BairdMedline price target raised to $56 from $48 at Baird

Pito Chickering

Deutsche Bank

$40→$48

Hold

7.74%

Upside

Reiterated

02/26/26

Medline price target raised to $48 from $40 at Deutsche BankMedline price target raised to $48 from $40 at Deutsche Bank

Glen Santangelo

Barclays

$50

Buy

12.23%

Upside

Reiterated

02/26/26

Barclays Sticks to Its Buy Rating for Medline, Inc. Class A (MDLN)

Kevin Caliendo

UBS

$48→$57

Buy

27.95%

Upside

Reiterated

02/26/26

Medline price target raised to $57 from $48 at UBSMedline price target raised to $57 from $48 at UBS

Lee Hambright

Bernstein

$49→$56

Buy

25.70%

Upside

Assigned

02/26/26

Medline price target raised to $56 from $49 at BernsteinMedline price target raised to $56 from $49 at Bernstein

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Medline

3 Months

xxx

Success Rate

1/2 ratings generated profit

Average Return

-2.80%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of -2.80% per trade.

1 Year

Ryan HalstedRBC Capital

Success Rate

1/2 ratings generated profit

Average Return

-2.80%

a rating ―

Copying Ryan Halsted's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -2.80% per trade.

2 Years

xxx

Success Rate

1/2 ratings generated profit

Average Return

-2.80%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of -2.80% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MDLN Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, MDLN has received 51 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. MDLN average Analyst price target in the past 3 months is 52.35.

Each month's total comprises the sum of three months' worth of ratings.

MDLN Financial Forecast

MDLN Earnings Forecast

Next quarter’s earnings estimate for MDLN is $0.24 with a range of $0.21 to $0.26. The previous quarter’s EPS was $0.23. MDLN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate ― of the time in the same period. In the last calendar year MDLN has its overall industry.

MDLN Sales Forecast

Next quarter’s sales forecast for MDLN is $7.51B with a range of $7.33B to $7.57B. The previous quarter’s sales results were $7.79B. MDLN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates ― of the time in the same period. In the last calendar year MDLN has its overall industry.

MDLN Stock Forecast FAQ

What is MDLN’s average 12-month price target, according to analysts?

Based on analyst ratings, Medline’s 12-month average price target is 52.35.

What is MDLN’s upside potential, based on the analysts’ average price target?

Medline has 17.50% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is MDLN a Buy, Sell or Hold?

Medline has a consensus rating of Strong Buy which is based on 23 buy ratings, 4 hold ratings and 0 sell ratings.

What is Medline’s price target?

The average price target for Medline is 52.35. This is based on 27 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $60.00 ,the lowest forecast is $38.00. The average price target represents 17.50% Increase from the current price of $44.55.

What do analysts say about Medline?

Medline’s analyst rating consensus is a Strong Buy. This is based on the ratings of 27 Wall Streets Analysts.

How can I buy shares of MDLN?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Medline (MDLN) Stock Forecast & Price Target

MDLN Analyst Ratings

MDLN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Medline

MDLN Analyst Recommendation Trends

MDLN Financial Forecast

MDLN Earnings Forecast

MDLN Sales Forecast

MDLN Stock Forecast FAQ

Detailed List of Analyst Forecasts